Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
FIBD1 | PROMETHEUS IBD sgi Diagnostic, S | No | Yes |
FIBD2 | PROMETHEUS IBD sgi Diagnostic, B | No | Yes |
Enzyme Linked Immunosorbent Assay (ELISA), Chemiluminescent, Immunofluorescence Assay (IFA), multiplexed Polymerase Chain Reaction (PCR) allelic discrimination assays.
SGI
Serum
Whole Blood EDTA
Requires both whole blood and serum
Note: Specimens must be shipped together
Note: Informed consent required from NYS clients
Blood:
Collect 2 mL lavender top EDTA whole blood. Ship refrigerate.
Serum:
Draw blood in a plain, red-top tube(s). (Serum gel tube is acceptable.) Spin down and send 2 mL of serum refrigerated.
Blood = 2 mL, Serum = 2 mL
Thawing** | Cold OK; Warm OK |
other reasons for rejection | If both serum and EDTA whole blood are not received. |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 21 days | |
Ambient | 7 days | ||
Whole Blood EDTA | Refrigerated (preferred) | 21 days | |
Ambient | 7 days |
Combines serologic, genetic, and inflammation markers to help differentiate Inflammatory Bowel Disease (IBD) vs non-IBD and ulcerative colitis (UC) vs Crohn's disease (CD).
The PROMETHEUS IBD sgi Diagnostic is the 4th-generation IBD diagnostic test and the first and only test to combine serologic, genetic, and inflammation markers in the proprietary Smart Diagnostic Algorithm for added diagnostic clarity. This test aids healthcare providers in differentiating IBD vs non-IBD and CD vs UC in one comprehensive blood test. This assay includes 9 serological markers ASCA IgA, ASCA IgG and proprietary markers anti-Fla-X, anti-A4-Fla2, anti-CBir1, anti-OMPC, and DNAse-sensitive pANCA that helps identify patients with IBD and utilizes Smart Diagnostic Algorithm Technology to improve the predictive accuracy. Genetic susceptibility influences immune responses, and this assay includes evaluation of ATG16L1, STAT3, NKX2-3, and ECM1. Inflammatory markers include VEGF, ICAM-1, VCAM-1, CRP, SAA. While most other labs only offer assay values, PROMETHEUS IBD sgi Diagnostic provides added clarity in diagnosing IBD, UC, and CD.
Testing is complete. Final report has been sent to the referring laboratory.
A proprietary algorithm is applied to the serologic, genetic, and inflammatory markers.
Monday through Friday
Test results should be used in conjunction with other clinical and diagnostic findings. The healthcare provider is responsible for the use of this information in the management of their patient. The test was developed, and it's performance characteristics determined by Prometheus. It has not been cleared or approved by the U.S. FDA. The test is used for clinical purposes and should not be regarded as investigational or for research. Prometheus is CAP-accredited (6805501) and CLIA-certified (05D0917432) as qualified to perform high complexity testing. The test may be covered by one or more U.S. pending or issued patents-refer to prometheuslabs.com
PROMETHEUS and IBD sgi Diagnostic, are trademarks or registered trademarks of Prometheus Laboratories Inc., San Diego, California. All other trademarks and service marks are the property of their respective owners.
82397 x 4
83520 x 6
86255 x 2
81479
86140
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
FIBDD | PROMETHEUS IBD sgi Diagnostic | Not Provided |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
Z2743 | PROMETHEUS IBD sgi Diagnostic, S | Unable to Verify |
Z2744 | PROMETHEUS IBD sgi Diagnostic, B | Unable to Verify |